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Sir, 13 
 The emergence of carbapenemase-mediated resistance to all the β-lactam, including 14 
the carbapenem is a major public health threat. In Enterobacteriaceae, one of the most 15 
frequent carbapenemases is the Klebsiella pneumoniae carbapenemase (KPC) enzymes [1-3]. 16 
Since the first KPC-producing isolate was identified from North Carolina, United States in 17 
1996, occurrence of KPC-producing bacteria have been reported in other parts of the United 18 
States, Europe, South America, the Middle East and Asia [1,2]. In September 2010, Hong 19 
Kong set up an enhanced surveillance system for detection of carbapenem-resistant 20 
Enterobacteriaceae; following recent concerns that the transmission of these extensively 21 
resistant organisms may be associated with medical tourism or surgery abroad in areas where 22 
they are endemic [1-3]. In all the public hospitals, all newly admitted patients with potential 23 
risk factors for carbapenem-resistant Enterobacteriaceae (e.g. overseas hospitalization) will 24 
be actively screened for colonization. In clinical microbiology laboratories, all carbapenem-25 
resistant Enterobacteriaceae isolates will be assessed for carbapenemase activity using 26 
inhibition tests with boronic acid and ethylene diamine tetra-acetic acid (EDTA) [1]. Isolates 27 
with positive carbapenemase screen test will be sent to the public health laboratory for 28 
molecular characterization. Additionally, strains of carbapenem-resistant Enterobacteriaceae 29 
previously stored in MicroBank (Pro-Lab Diagnostics Inc., Canada) at -80 oC in a regional 30 
hospital in Hong Kong were retrieved for testing. This lead to the retrospective identification 31 
of the first case of KPC-producing K. pneumoniae in Hong Kong and the findings were 32 
reported here. 33 
In August 2006, a multidrug-resistant Klebsiella pneumoniae isolate was recovered from 34 
the mid-stream urine sample of a 75 year old lady who attended an outpatient clinic for 35 
follow-up. She has history of diabetes mellitus, hypertension and atrial fibrillation. Patient 36 
travelled to the United States frequently and sometimes had medical follow up there. Past 37 
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health was relevant for a history of cholecystectomy in New York, United States in July 2005. 38 
She was totally asymptomatic with no fever or any urinary symptom. Her WBC count was 39 
normal. No antibiotic was given. Personal hygiene was advised. The isolate was identified as 40 
K. pneumoniae using a Vitek system (GNI, bioMerieux, Hazelwood, USA). Disc diffusion 41 
test showed that the isolate was resistant to cephalosporins (ceftriaxone, ceftazidime, 42 
cefepime), beta-lactam-β-lactamase inhibitor combinations (amoxicillin-calvulanate, 43 
piperacillin-tazobactam), imipenem, ciprofloxacin, chloramphenicol, aminoglycosides 44 
(amikacin, gentamicin, and netilmicin), nitrofurantoin, and cotrimoxazole at the CLSI 45 
breakpoints [4]. For these drugs, there was no inhibition zone or very small inhibition zone 46 
around the discs. The MIC for the following drugs was determined by Etest (AB Biodisk, 47 
Solna, Sweden): meropenem (32 µg/ml, resistant), imipenem (32 µg/ml, resistant), 48 
fosfomycin (24 µg/ml, sensitive) and colistin (0.38 µg/ml, sensitive).  49 
The isolate was retrieved and tested for primers specific for the KPC genes. A positive 50 
PCR result was obtained. Subsequent sequencing showed that a KPC-2 gene was carried by 51 
the isolate. In order to identify the genetic background of this strain, the organism was 52 
characterized by multilocus sequencing (MLST) [2,3]. This strain has an allelic profile 3-3-1-53 
1-1-1-79 (gapA-infB-mdh-pgi-phoE-rpoB-tonB), corresponding to ST258. In the United 54 
States, this clone has disseminated widely and accounted for 70% of the national collection 55 
from 1996 to 2008 [2]. In contrast, the dominant KPC clone in mainland China is an ST11 56 
variant with the allelic profile 3-3-1-1-1-1-4 [3]. The finding suggests that our patient has 57 
likely acquired the organism from the United States during her previous travel visits. 58 
This case raises several important issues. Firstly, the importation of multidrug-resistant 59 
bacteria, such as carbapenem-resistant Enterobacteriaceae among patients with history of 60 
medical treatment abroad may be underestimated. Kennedy et al reported that colonization 61 
with E. coli resistant to gentamicin, ciprofloxacin and/or third generation cephalosporins 62 
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increased from 7.8% at baseline to 49% after international travel [5]. In 18% of the 63 
individuals, prolonged colonization for over 6 months occurred [5]. These individuals may 64 
act as reservoirs for infection within the community or sources of outbreak when they are 65 
hospitalized [2,3,5]. In many countries, there are no national guidelines for admission 66 
screening of individuals who have history of medical treatment abroad. Secondly, the optimal 67 
treatment for invasive carbapenem-resistant Enterobacteriaceae infections is uncertain and is 68 
complicated by the frequent occurrence of co-resistance to many other antibiotics. The agents 69 
that are potentially active against carbapenem-resistant Enterobacteriaceae are colistin, 70 
tigecycline, fosfomycin and isepamicin. In solid organ and bone marrow transplant recipient, 71 
infections by these organisms represent tremendous threat. In response to these challenges, 72 
hospitals in Hong Kong have recently introduced active screening for carbapenem-resistant 73 
Enterobacteriaceae carriage at hospital admission. Under the arrangement, all newly admitted 74 
patients with history of hospitalization, surgery or dialysis in an overseas institution in the 75 
previous 12 months would be screened.     76 
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